Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 09, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On November 08, 2006, administrators notified the company of an increase in interests in Ordinary Share ADRs for specific individuals. These transactions occurred at a price of $53.89 per ADR following the re-investment of the dividend paid to shareholders on October 05, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider share holdings.
Important Facts for Investors
- Transaction Date: November 08, 2006.
- Transaction Type: Increase in Ordinary Share ADR interests via dividend re-investment.
- Price per ADR: $53.89.
- Dividend Re-investment Date: October 05, 2006.
- Individuals Notified: Dr JP Garnier (1,300.00 ADRs), Dr F Calhoun (132.87 ADRs), Mr D Phelan (250.73 ADRs), and Mr D Stout (100.22 ADRs).